Elevation of von Willebrand factor levels in patients with IgA nephropathy: Effect of ACE inhibition

American Journal of Kidney Diseases

Volumn 30, Issue 3, 1997, Pages 397-403

  Hernandez, E ^a   Toledo, T ^a   Alamo, C ^a   Mon, C ^a   Rodicio, J L ^a   Praga, M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

ACE inhibitors; Endothelial dysfunction; IgA nephropathy; Proteinuria; von Willebrand factor

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; VON WILLEBRAND FACTOR;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; AUTOANALYSIS; BLOOD SAMPLING; CALCULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; FEMALE; HUMAN; IMMUNOELECTROPHORESIS; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PROTEINURIA; QUALITATIVE DIAGNOSIS;

EID: 0030848452     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90285-7     Document Type: Article

References (36)

1. D'Amico G The commonest glomerulonephritis in the world: IgA nephropathy Q J Med 64 1987 709 727
2. Julian BA Waldo BF Rifal A Mesteck J IgA nephropathy, the most common glomerulonephritis worldwide Am J Med 84 1988 129 134
3. Rodicio JL Idiopathic IgA nephropathy Kidney Int 25 1984 717 729
4. D'Amico G Imbasciati E Barbiano de Belgoioso G Bertoli S Fogazzi G Ferrario F Fellin G Ragni A Colasanti G Minetti L Ponticelli C Idiopathic IgA mesangial nephropathy Clinical and histological study of 374 patients ed 3 Medicine 64 1985 49 60
5. Schena FP A retrospectie analysis of the natural history of primary IgA nephropathy worldwide Am J Med 89 1990 209 215
6. Feiner HD Cabili S Baldwin DS Schacht RG Gallo GR Intrarenal vascular sclerosis in IgA nephropathy Clin Nephrol 18 1982 183 192
7. Gallo GR Katafuchi R Neelankantappa K Baldwin DS Prognostic pathologic markers in IgA nephropathy Am J Kidney Dis 12 1988 362 365
8. Katafuchi R Vamvakas E Neelankantappa K Baldwin DS Gallo GR Microvascular disease and the progression of IgA nephropathy Am J Kidney Dis 15 1990 72 79
9. Boneu B Abbal M Plante J Bierne R Factor-VIII complex and endothelial cell damage Lancet 1 1975 1430
10. Jensen T Bjerre-Knudsen J Feldt-Rasmussen B Deckert T Features of endothelial dysfunction in early diabetic nephropathy Lancet 1 1989 461 463
11. Suffredini AF Harpel PC Parrillo JE Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects N Engl J Med 320 1989 1165 1172
12. Pedrinelli R Giampietro O Carmassi F Melillo E Dell'Plmo G Catapano G Matteucci E Talarico L Morale M Da Negri F Di Bello V Microalbuminuria and endothelial dysfuncton in essential hypertension Lancet 344 1994 14 18
13. Bloom AL von Willebrand factor: Clinical features of inherited and acquired disorders Mayo Clin Proc 66 1991 743 751
14. Sakariassen KS Bolhuis PA Sixma JJ Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to subendothelium Nature 279 1979 636 638
15. Vukovich TC Schernthaner G Knobi PN Hay U The effect of near-normoglycemic control on plasma factor VIII/von Willebrand factor and fibrin degradation products in insulin-dependent diabetic patients J Clin Endocrinol Metab 69 1989 84 89
16. Stehouwer CDA Stroes ESG Hackeng WHL Mulder PGH Ottolander GJH von Willebrand factor and development of diabetic nephropathy in IDDM Diabetes 40 1991 971 976
17. Stehouwer CDA Zellenrath P Polak BCP Baarsma G Nauta JJP Donker AJM Ottolander GJH von Willebrand factor and early diabetic retinopathy: No evidence for a relationship in patients with type 1 (insulin-dependent) diabetes mellitus and normal urinary albumin excretion Diabetologia 35 1992 555 559
18. Stehouwer CDA Nauta JJP Zeldendrust GC Hackeng WHL Donker AJM Ottolander GJH Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus Lancet 340 1992 319 323
19. Iwashima Y Sato T Watanabe K Ooshima E Hiraishi S Ishii H Kazama M Makino I Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy Diabetes 39 1990 983 988
20. Deckert T Feldt-Rasmussen B Borch-Thonsen K Jensen T Kofoed-Enovoldsen A Albuminuria reflects wide-spread vascular damage The Steno hypothesis ed 3 Diabetologia 32 1989 219 226
21. Laurell CB Quantitative estimation of proteins by electrophoresis in agarosa gel containing antibodies Anal Biochem 15 1966 45 52
22. Ross R The pathogenesis of atherosclerotic: An update N Engl J Med 314 1986 488 500
23. Vane JR Angaard EE Botting RM Mechanisms of disease: Regulatory functions of the vascular endothelium N Engl J Med 323 1990 27 36
24. Kanwar YS Biophysiology of glomerular filtration and proteinuria Lab Invest 51 1984 7 21
25. Yap HK Sakai RS Bahn L Rappaport V Woo KT Ananthuraman V Lim CH Chiang GS Jordan SC Antivascular endothelial cell antibodies in patients with IgA nephropathy: Frequency and clinical significance Clin Immunol Immunopathol 49 1988 450 462
26. Fornasieri A Pinerolo C Bernasconi P Li M Armelloni S Gibelli A D'Amico G Anti-mesangial and anti-endothelial cell antibodies in IgA mesangial nephropathy Clin Nephrol 44 1995 71 78
27. Feriozzi S Pierucci A Roscia E Cinotti GA Pecci G Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy J Hypertens 7 1989 S63 S64
28. Okamura M Kanayama Y Negoro N Inoue T Takeda T Long-term effects of calcium antagonist and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy Contrib Nephrol 90 1991 161 165
29. Remuzzi A Pertucucci E Ruggenenti P Mosconi L Limonta M Remuzzi G Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy Kidney Int 39 1991 1267 1273
30. Praga M Hernández E Montoyo C Andres A Ruilope LM Rodicio JL Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria Am J Kidney Dis 20 1992 240 248
31. Maschio G Cagnoli L Claroni F Fusaroli M Rugiu C Sanna G Sasdelli M Zuccala A Zuccheli P ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study Nephrol Dial Transplant 9 1994 265 269
32. Anderson S Rennke HG Brenner BM Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension J Clin Invest 77 1986 1993 2000
33. Vanhoutte PM Boulanger CM Illiano SC Nagao T Vidal M Mombouli JV Endothelium-dependent effects of converting-enzyme inhibitors J Cardiovasc Pharmacol 22 1993 S10 S16
34. Powell JS Clozel JP Muller RK Kuhn H Hefti F Hosang M Baumgartner HR Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury Science 245 1989 186 188
35. Farhy RD Carretero OA Khang-LOon H Scicli G Role of kinins and nitric oxide in the effects of angiotensin-converting inhibitors on neointima formation Circ Res 7 1993 1202 1210
36. Hutchison FN Cui X Webster SK The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin J Am Soc Nephrol 6 1995 1216 1222